MedTrace Logo

A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers

NCT02700373 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-02-23

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of PDC-APB by intramuscular (IM) injection compared to placebo.

Conditions

  • Contact Dermatitis

Interventions

DRUG

PDC-APB

DRUG

Placebo

Sponsors & Collaborators

  • Hapten Sciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Chad S Boomershine, MD · Clinical Research Solutions

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2018-01-31
Completion
2018-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02700373 on ClinicalTrials.gov